Skip to content
← Survival collections

CANCER EVIDENCE

5-Year Survival

70 published cancer groups · 65,440 source series. Choose a group to explore its populations.

Acute Lymphocytic Leukemia (ALL)

240 source series

→

Acute Monocytic Leukemia (AML-M5)

240 source series

→

Acute Myeloid Leukemia (AML)

240 source series

→

Adenocarcinoma of the Esophagus

1,200 source series

→

Adenocarcinoma of the Lung and Bronchus

1,200 source series

→

All Cancer Sites Combined

240 source series

→

Anus, Anal Canal & Anorectum

1,200 source series

→

Bones and Joints

1,200 source series

→

Brain and Other Nervous System

1,200 source series

→

Breast

800 source series

→

Cervix Uteri

400 source series

→

Chronic Lymphocytic Leukemia (CLL)

240 source series

→

Chronic Myeloid Leukemia (CML)

240 source series

→

Chronic Myelomonocytic Leukemia (CMML)

240 source series

→

Chronic myeloproliferative disorders (CMD)

240 source series

→

Colon (including Appendix)

1,200 source series

→

Colon and Rectum (excluding Appendix)

1,200 source series

→

Colon and Rectum (including Appendix)

1,200 source series

→

Corpus and Uterus, NOS

400 source series

→

Diffuse Astrocytoma and Anaplastic Astrocytoma of the Brain and ONS

1,200 source series

→

Embryonal Tumors of the Brain and ONS

1,200 source series

→

Esophagus

1,200 source series

→

Eye and Orbit

1,200 source series

→

Floor of Mouth

1,200 source series

→

Follicular Subtype of the Thyroid

1,200 source series

→

Gallbladder

1,200 source series

→

Glioblastoma of the Brain and ONS

1,200 source series

→

Gum & other mouth

1,200 source series

→

Hodgkin Lymphoma

1,200 source series

→

HR-/HER2- Breast Cancer (Female only)

400 source series

→

HR-/HER2+ Breast Cancer (Female only)

400 source series

→

HR+/HER2- Breast Cancer (Female only)

400 source series

→

HR+/HER2+ Breast Cancer (Female only)

400 source series

→

Kaposi Sarcoma

1,200 source series

→

Kidney

1,200 source series

→

Kidney and Renal Pelvis

1,200 source series

→

Large Cell Carcinoma of the Lung and Bronchus

1,200 source series

→

Larynx

1,200 source series

→

Leukemia

240 source series

→

Lip

1,200 source series

→

Liver and Intrahepatic Bile Duct

1,200 source series

→

Lung and Bronchus

1,200 source series

→

Melanoma of the Skin

1,200 source series

→

Meningioma of the Brain and ONS

1,200 source series

→

Mesothelioma

1,200 source series

→

Myelodysplastic syndromes (MDS)

240 source series

→

Myeloma

1,200 source series

→

Non-Hodgkin Lymphoma

1,200 source series

→

Oral Cavity and Pharynx

1,200 source series

→

Oropharynx & Tonsil

1,200 source series

→

Other Glioma of the Brain and ONS

1,200 source series

→

Ovary

400 source series

→

Pancreas

1,200 source series

→

Papillary Subtype of the Thyroid

1,200 source series

→

Prostate

400 source series

→

Rectum

1,200 source series

→

Renal Pelvis

1,200 source series

→

Salivary Gland

1,200 source series

→

Small cell carcinoma of the Lung and Bronchus

1,200 source series

→

Small Intestine

1,200 source series

→

Soft Tissue including Heart

1,200 source series

→

Squamous Cell Carcinoma of the Esophagus

1,200 source series

→

Squamous Cell Carcinoma of the Lung and Bronchus

1,200 source series

→

Stomach

1,200 source series

→

Testis

400 source series

→

Thyroid

1,200 source series

→

Tongue

1,200 source series

→

Urinary Bladder (Invasive & In Situ)

1,440 source series

→

Vagina

400 source series

→

Vulva

400 source series

→

Preserved source evidence · Independent clinical review pending · Not medical advice

SEER survival populations | Triangle